Evidence map›Paper›PMID 37483227›Full record

ArticleACS omega2023

Development of a Radiolabeled Folate-Mediated Drug Delivery System for Effective Delivery of Docetaxel.

Oğuz Çetin, Burcu Güngör, Çiğdem İçhedef, Yasemin Parlak, Elvan Sayıt Bilgin, Funda Üstün, Gülay Durmuş Altun, Yücel Başpınar, Serap Teksöz

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Oğuz ÇetinDepartment of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir 35100, Turkey.
Burcu GüngörDepartment of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir 35100, Turkey.
Çiğdem İçhedefDepartment of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir 35100, Turkey.
Yasemin ParlakDepartment of Nuclear Medicine, School of Medicine, Celal Bayar University, Manisa 45040, Turkey.
Elvan Sayıt BilginDepartment of Nuclear Medicine, School of Medicine, Celal Bayar University, Manisa 45040, Turkey.
Funda ÜstünDepartment of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne 22030, Turkey.
Gülay Durmuş AltunDepartment of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne 22030, Turkey.
Yücel BaşpınarDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, Izmir 35040, Turkey.
Serap TeksözDepartment of Nuclear Applications, Institute of Nuclear Sciences, Ege University, Izmir 35100, Turkey.ORCID https://orcid.org/0000-0002-6780-5159
Ege University · TRManisa Celal Bayar University · TRTrakya University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many preclinical studies are carried out with the aim of developing new formulations for the effective delivery of taxane class drugs, one of the most important anticancer drugs used clinically today. In this study, a radiolabeled folate-mediated solid lipid magnetic nanoparticle (SLMNP) system was developed by loading superparamagnetic iron oxide nanoparticles (MNP) and docetaxel (DTX) into the solid lipid nanoparticles as a drug delivery system that will function both in cancer treatment and diagnosis. For this purpose, first, SLMNP was synthesized by the hot homogenization method, and the surface of the particles was modified with a folate derivative to carry the particles to tissues with folate receptors. The synthesized magnetic solid lipid nanoparticles were loaded with DTX, and then radiolabeling was carried out with technetium-99 m (

Identifiers

PMID37483227
PMCPMC10357535
OpenAlexW4383070168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.